Hyaluronic Acid With Polyethylene Glycol 400 With Propylene Glycol With Hydroxypropyl Guar
Noted OphthalmologyAuthority RequiredNot applicable line
Treatment of severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.
1
Submissions
2023–23
On the record
—
ICER range
Cost-min
Cost basis
Decisions on record
- Meeting Jul 2025 Noted Severe dry eye syndrome no PSD
- Meeting May 2023 Recommended Severe dry eye syndrome in patients sensitive to preservatives
- Meeting Mar 2023 Deferred Severe dry eye syndrome in patients sensitive to preservatives in multi-dose eye drops no PSD
Access path
- May 2023Recommended
vs lowest cost PBS listed ocular lubricant
- PBS listing · Authority Required
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
6.1 The PBAC deferred making a recommendation to list Systane Hydration for the treatment of severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops in order to undertake further analysis of the cost effectiveness of ocular lubricants.PSD · May 2023
6.2 The PBAC recalled that, at its July 2020 consideration of Cationorm, it considered the cost minimisation comparison of hyaluronate 0.1/0.2% to Cationorm was appropriate, advising that ‘all preservative free, multi-dose ocular lubricants currently listed on the PBS were appropriate comparators for Cationorm’ (paragraph 6.2, Cationorm PSD, July 2020 PBAC Meeting).PSD · May 2023
Economic analysis
5.20 The submission presented a cost-minimisation approach (CMA) comparing Systane Hydration with Hylo-Fresh/Hylo-Forte and Cationorm respectively.PSD · May 2023
5.21 The submission claimed a PBS listing for Systane Hydration is not expected to result in changes in resource use due to differences in prescribing or the administration profiles, adverse events or monitoring requirements. The CMA included the cost of the medicines only and was undertaken on a treatment basis, defined as one drop in both eyes.PSD · May 2023
Clinical claim
5.18 The submission claimed the non-inferior comparative effectiveness and non-inferior comparative safety of Systane Hydration compared with Hylo-fresh, Hylo-Forte and Cationorm respectively.PSD · May 2023
5.19 The PBAC considered that the claim of non-inferior comparative effectiveness and non-inferior comparative safety was reasonable.PSD · May 2023
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated.
The PBAC recommended the listing of Systane Hydration for the treatment of severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops on a cost-minimisation basis to the lowest cost PBS listed ocular lubricant. PBAC · 2023
Cost-effectiveness accepted
Decision context
PopulationPatients with severe dry eye syndrome who are sensitive to preservatives in multi-dose eye drops.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| May 2023 | Recommended | lowest cost PBS listed ocular lubricant | — | RCT · Ocular surface score (OSS) |
Clinical evidence
| Trial | Phase | N | Primary outcome | Status |
|---|---|---|---|---|
| Labetoulle et al 2018 (NCT02470429) | NA | 114 | Change From Baseline in Total Ocular Surface Staining (TOSS) Score at Day 42 | completed |